Center For Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$201K Buy
+405
New +$179K 0.09% 150
2026
Q1
Sell
-677
Closed -$307K 154
2025
Q4
$307K Buy
+677
New +$292K 0.16% 112
2024
Q3
Sell
-1,714
Closed -$803K 130
2024
Q2
$803K Sell
1,714
-10
-0.6% -$4.34K 0.53% 45
2024
Q1
$721K Hold
1,724
0.59% 39
2023
Q4
$701K Sell
1,724
-1,196
-41% -$442K 0.64% 38
2023
Q3
$1.02M Sell
2,920
-86
-3% -$30.1K 1.01% 25
2023
Q2
$1.06M Buy
3,006
+1,979
+193% +$667K 1% 26
2023
Q1
$324K Buy
+1,027
New +$308K 0.32% 79

Other funds holding VRTX

Center For Asset Management's VRTX Position: Q2 2026 in Review

Center For Asset Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 405 shares worth $201K. The stake represents 0.09% of the portfolio and ranks #150 among its holdings. This is a return to the name: Center For Asset Management previously reported a position in VRTX as recently as Q4 2025.

Center For Asset Management first reported a position in VRTX in Q1 2023 and has held it in 8 quarters since. The position peaked at $1.06M in Q2 2023. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Center For Asset Management held 405 shares of Vertex Pharmaceuticals worth $201K as of Q2 2026.
  • Vertex Pharmaceuticals was a new Center For Asset Management position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.09% of Center For Asset Management's portfolio in Q2 2026, its #150 holding.
  • Center For Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 8 quarters since.
  • Center For Asset Management's Vertex Pharmaceuticals position peaked at $1.06M in Q2 2023.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Center For Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.